2-Bromo-5-(trimethylstannyl)pyridine | 225932-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Bromo-5-(trimethylstannyl)pyridine
• 英文别名: 3-(trimethylstannyl)-6-bromopyridine；2-bromo-5-trimethylstannylpyridine；6-bromo-3-(trimethylstannyl)pyridine；(6-bromopyridin-3-yl)-trimethylstannane
• CAS: 225932-26-3
• 化学式: C₈H₁₂BrNSn
• 分子量: 320.804
• InChiKey: PSWRSWODAIRCSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.39
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Bromo-5-(trimethylstannyl)pyridine 在 正丁基锂 作用下， 以 乙醚 为溶剂， 生成 6'-Bromo-5-(3-methoxy-phenyl)-[2,2']bipyridinyl
  参考文献：
  名称：

  摘要：

  DOI：

  10.5555/ol007052d
• 作为产物：
  描述：

  2,5-二溴吡啶 、 三甲基氯化锡 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 4.5h， 以37%的产率得到2-Bromo-5-(trimethylstannyl)pyridine
  参考文献：
  名称：

  Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them

  摘要：

  公式（I）所选的化合物如下： 其中： X代表氧或硫， Y代表氧，-NH-或-N（C1-C6）烷基-， Ra代表氢，卤素，（C1-C3）烷基，羟基或（C1-C3）甲氧基， Rb代表氢，卤素或（C1-C3）烷基， A代表苯基，吡啶基，（C5-C6）环烷基或（C5-C6）环烯基， R1和R2分别代表从氢，卤素，氰基，硝基，卤代烷基，卤代甲氧基，烷基，烯基，炔基，-OR4，-NR4R5，-S（O）nR4，-C（O）R4，-CO2R4，-O—C（O）R4，-C（O）NR4R5，-NR5—C（O）R4，-NR5—SO2R4，-T-CN，-T-OR4，-T-OCF3，-T-NR4R5，-T-S（O）nR4，-T-C（O）R4，-T-CO2R4，-T-O—C（O）R4，-T-C（O）NR4R5，-T-NR4—C（O）R5，-T-NR4—SO2R5，-R6和-T-R6中选择的基团，其中n，T，R4，R5和R6如描述中所定义， R3代表-R7或-U-R11基团，其中R7代表氢，烷基，芳基，环烷基或杂环烷基，U代表线性或支链烷基链，R11如描述中所定义， 它们的光学异构体或它们与药学上可接受的酸或碱形成的加合盐，以及它们作为金属蛋白酶抑制剂，更具体地是金属蛋白酶-12的抑制剂的用途。

  公开号：

  US20040072871A1

文献信息

• Synthesis of Aryl Trimethylstannanes from Aryl Amines: A Sandmeyer-Type Stannylation Reaction
  作者：Di Qiu、He Meng、Liang Jin、Shuai Wang、Shengbo Tang、Xi Wang、Fanyang Mo、Yan Zhang、Jianbo Wang

  DOI：10.1002/anie.201304579

  日期：2013.10.25

  Sandmeyer‐type stannylation: Stille coupling is one of the most powerful coupling reactions for CC bond formation, whereas there are only limited methods to access aryl stannane compounds. A mild stannylation process based on a Sandmeyer‐type transformation using aromatic amines as the starting materials is described. DCE: 1,2‐dichloroethane.

  桑德迈尔型甲锡烷基化：Stille偶联是C中的最强大的偶联反应中的一个 C键的形成，而也有只限于方法来访问芳基锡烷化合物。描述了基于Sandmeyer型转化的温和锡烷基化工艺，该工艺使用芳族胺作为起始原料。DCE：1,2-二氯乙烷。
• New Parts for a Construction Set of Bifunctional Oligo(het)arylene Building Blocks for Modular Chemistry
  作者：Govindaswamy Manickam、A. Dieter Schlüter

  DOI：10.1055/s-2000-6344

  日期：——

  The 100 mg to 5 g scale synthesis of a variety of arylene (6, 11, 13) and hetarylene building blocks (15, 17, 18) by and for Suzuki/Stille type cross-coupling reactions is reported. These building blocks carry solubilizing hexyloxymethyl substituents as well as boronic acid ester and Br/I functionalities. This considerably widens the already existing construction set for the modular chemistry approach to shape persistent and functional compounds on the nanometer scale.

  据报道，通过 Suzuki/Stille 型交叉偶联反应合成了 100 mg 至 5 g 规模的各种亚芳基 (6、11、13) 和亚芳基结构单元 (15、17、18)。这些结构单元带有增溶性己氧基甲基取代基以及硼酸酯和 Br/I 官能团。这大大拓宽了模块化化学方法现有的结构集，以在纳米尺度上形成持久性和功能性化合物。
• 5-Substituted Derivatives of 6-Halogeno-3-((2-(<i>S</i>)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(<i>S</i>)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α4β2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity:  Potential Probes for Imaging with Positron Emission Tomography
  作者：Yi Zhang、Olga A. Pavlova、Svetlana I. Chefer、Andrew W. Hall、Varughese Kurian、LaVerne L. Brown、Alane S. Kimes、Alexey G. Mukhin、Andrew G. Horti

  DOI：10.1021/jm030432v

  日期：2004.5.1

  Potential positron emission tomography (PET) ligands with low picomolar affinity at the nicotinic acetylcholine receptor (nAChR) and with lipophilicity (log D) ranging from -1.6 to +1.5 have been synthesized. Most members of the series, which are derivatives of 5-substituted-6-halogeno-A-85380, exhibited a higher binding affinity at alpha4beta2-nAChRs than epibatidine. An analysis, by molecular modeling, revealed an important role of the orientation of the additional heterocyclic ring on the binding affinity of the ligands with nAChRs. The existing nicotinic pharmacophore models do not accommodate this finding. Two compounds of the series, 6-[F-18]-fluoro-5-(pyridin-3-yl)-A-85380 ([F-18]31) and 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2- [F-18]-fluoropyridin-5-yl)pyridine) ([F-18]35), were radiolabeled with F-18. Comparison of PET data for [F-18]31 and 2-[F-18]FA shows the influence of lipophilicity on the binding potential. Our recent PET studies with [F-18]35 demonstrated that its binding potential values in Rhesus monkey brain were ca. 2.5 times those of 2-[F-18]FA. Therefore, [F-18]35 and several other members of the series, when radiolabeled, will be suitable for quantitative imaging of extrathalamic nAChRs.
• Lehmann, Uwe; Dieter Schlueter, European Journal of Organic Chemistry, 2000, # 20, p. 3483 - 3487
  作者：Lehmann, Uwe、Dieter Schlueter

  DOI：——

  日期：——
• Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them
  申请人：——

  公开号：US20040072871A1

  公开（公告）日：2004-04-15

  A compound of formula (I) selected from: 1 wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C 1 -C 6 )alkyl-, R a represents hydrogen, halogen, (C 1 -C 3 )alkyl, hydroxyl or (C 1 -C 3 )alkoxy, R b represents hydrogen, halogen or (C 1 -C 3 )alkyl, A represents phenyl, pyridyl, (C 5 -C 6 )cycloalkyl or (C 5 -C 6 )cycloalkenyl, R 1 and R 2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR 4 , —NR 4 R 5 , —S(O) n R 4 , —C(O)R 4 , —CO 2 R 4 , —O—C(O)R 4 , —C(O)NR 4 R 5 , —NR 5 —C(O)R 4 , —NR 5 —SO 2 R 4 , -T-CN, -T-OR 4 , -T-OCF 3 , -T- NR 4 R 5 , -T-S(O) n R 4 , -T-C(O)R 4 , -T-CO 2 R 4 , -T-O—C(O)R 4 , -T-C(O)NR 4 R 5 , -T-NR 4 —C(O)R 5 , -T-NR 4 —SO 2 R 5 , —R 6 and -T-R 6 in which n, T, R 4 , R 5 and R 6 are as defined in the description, R 3 represents an —R 7 or —U—R 11 group in which R 7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R 11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.

  公式（I）所选的化合物如下： 其中： X代表氧或硫， Y代表氧，-NH-或-N（C1-C6）烷基-， Ra代表氢，卤素，（C1-C3）烷基，羟基或（C1-C3）甲氧基， Rb代表氢，卤素或（C1-C3）烷基， A代表苯基，吡啶基，（C5-C6）环烷基或（C5-C6）环烯基， R1和R2分别代表从氢，卤素，氰基，硝基，卤代烷基，卤代甲氧基，烷基，烯基，炔基，-OR4，-NR4R5，-S（O）nR4，-C（O）R4，-CO2R4，-O—C（O）R4，-C（O）NR4R5，-NR5—C（O）R4，-NR5—SO2R4，-T-CN，-T-OR4，-T-OCF3，-T-NR4R5，-T-S（O）nR4，-T-C（O）R4，-T-CO2R4，-T-O—C（O）R4，-T-C（O）NR4R5，-T-NR4—C（O）R5，-T-NR4—SO2R5，-R6和-T-R6中选择的基团，其中n，T，R4，R5和R6如描述中所定义， R3代表-R7或-U-R11基团，其中R7代表氢，烷基，芳基，环烷基或杂环烷基，U代表线性或支链烷基链，R11如描述中所定义， 它们的光学异构体或它们与药学上可接受的酸或碱形成的加合盐，以及它们作为金属蛋白酶抑制剂，更具体地是金属蛋白酶-12的抑制剂的用途。